Johannes Fischer - Profile and Investment Details

Investor Profile

Johannes Fischer is a Venture Capital, Private Equity Firm, Finance Operator based in Munich, Bavaria, Germany with a diverse investment portfolio that includes companies such as UiPath, Heliatek, import.io, invendo medical, Hintsa, ImevaX, Confo TherapeuticsZtory, Rigontec, Atopix Therapeutics, immatics biotechnologies, GLO, NEUWAY Pharma, TRiCares GmbH, ImCheck Therapeutics, Onfido, Themis Bioscience, Soundtrack Your Brand, Zopa, AYOXXA, YPlan, AMBOSS, 4SC, Edge Intelligence Software, Blackbuck, Polares Medical, Wool and the Gang, Middle Peak Medical, UroMems, 4TEEN4 Pharmaceuticals, EGenesis, Carisma Therapeutics, Minervax, Definiens, Nosto, GTX medical, STipe Therapeutics, Workframe, Dalia Research, Quanta, nyra health, SidekickHealth, Onward, Festicket, Artfinder, CorFlow, Mapillary, Orcan Energy, Jellynote, Hilo by Aktiia, Dacuda, SNIPR Biome, Koa Health, SumAll, Cavendish Kinetics, FREE NOW, EndoStim, IconOVir Bio, SuperSonic Imagine, opvizor, Tricares, Adrenomed, IOmx Therapeutics, EyeEm, Tonsser, SIRS Therapeutics, Genticel, . Over time, Johannes Fischer has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Johannes Fischer is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Digital Therapeutics, Regenerative Medicine, Genetics, Autonomous Vehicles, Wellness, Women Founded, Enterprise Software, Immunotherapy, Fundraising, Investment Management, Digital Media, Healthcare Innovation, Life Science, Portfolio Management, Medical Technologies, Banking, Information Technology (IT), Venture Fundraising, Mobile, Technology, Finance, Software, Biotechnology, Medical Devices, Genomics, Precision Medicine, Innovation, Clinical Trials, FinTech, Natural Language Processing, Consumer Internet, Consumer Software, Gene Therapy, Early Stage IT, EarlyStage Technology, Health Diagnostics, Digital Health, Medical, SaaS, Information Technology, B2B, Therapeutics, Cellular Therapy, Pharmaceuticals may find it worthwhile to explore potential connections with Johannes Fischer, as their portfolio suggests a familiarity and interest in this area.

Understanding Johannes Fischer’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.